Straits Times Index
3,322.62 +14.72 (+0.45%) S&P 500
5,281.59 -25.42 (-0.48%) Dow
39,148.43 -522.61 (-1.32%) Nasdaq
16,790.66 -10.89 (-0.06%) Bitcoin USD
67,734.55 -2,134.02 (-3.05%) CMC Crypto 200
1,474.55 -28.11 (-1.87%)
Genfit S.A. (0QT6.L)
| Previous close | 3.9505 |
| Open | 3.8360 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 3.8940 - 3.9300 |
| 52-week range | 3.1150 - 4.9000 |
| Volume | |
| Avg. volume | 22,360 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
Quorum of 27.25% on first convening; allowing approval of all the resolutions Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 22, 2024. The quorum on first convening amounted to 27.25% and sharehol
- GlobeNewswire
GENFIT Reports First Quarter 2024 Financial Information
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 14, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2024 and revenues for the first three months of 2024.1 Cash position As of March 31, 2024, the Company’s cash and cash equivalents amounted to €74.0 million compared with €128.6 million as
- GlobeNewswire
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
Lille (France), Cambridge (Massachusetts, USA), Zurich (Switzerland), April 25, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases, today announced the publication of its 2024 Extra-Financial Performance Report (fiscal year 2023). Third edition of the Extra-Financial Performance report Since 2022, GENFIT has published a detailed Extra-Financial Performance report in response to
